摘要
目的观察SLC29A1基因多态性-706G>C对急性白血病阿糖胞苷化疗疗效的影响。方法采用聚合酶链反应-直接测序(PCR-direct sequencing)法对使用阿糖胞苷治疗的104例急性髓性白血病患者进行基因分型,比较各基因型之间的疗效。结果突变型的完全缓解率及有效率明显高于GG型(57.9%vs 70.2%,64.9%vs 80.9%,P<0.05),突变型和GG型之间总生存率无明显差异(P>0.05)。结论 SLC29A1基因多态性-706G>C可显著提高AML阿糖胞苷化疗的CR率和ORR,但对总生存率未见明显影响。
Objective To identify the association between single-nucleotide polymorphism （SNP） of SLC29A1 G-706C and response to cytaraDine-containing chemotherapy in patients with acute myeloid leukemia. Methods Genotypes were determined using polymerase chain reaction（PCR）-direct sequencing in 104 acute myeloid leukemia patients treated with cytarabine and therapeutic effect was evaluated. Results CR and OR rate in GG group was significantly higher than that in mutation group （57.9% vs 70.2%,64.9% vs 80.9%,P〈0.05）. The difference of OS between two groups is not signifcant （P〉0.05）. Conclusion The SLC29A1 polymorphism of G-706C may improve CR and OR rate, but is not related to OS in patients treated with Cytarabine.
出处
《江西医药》
CAS
2015年第12期1366-1368,共3页
Jiangxi Medical Journal
基金
江西省科学技术厅社发领域科技项目(2009BSA11000)
